Free Trial

MyMD Pharmaceuticals (MYMD) Competitors

$2.00
+0.01 (+0.50%)
(As of 12:32 PM ET)

MYMD vs. NAVB, VRAX, BMRA, TRIB, CDIO, ARTL, THMO, CLVR, NUWE, and GNPX

Should you be buying MyMD Pharmaceuticals stock or one of its competitors? The main competitors of MyMD Pharmaceuticals include Navidea Biopharmaceuticals (NAVB), Virax Biolabs Group (VRAX), Biomerica (BMRA), Trinity Biotech (TRIB), Cardio Diagnostics (CDIO), Artelo Biosciences (ARTL), ThermoGenesis (THMO), Clever Leaves (CLVR), Nuwellis (NUWE), and Genprex (GNPX). These companies are all part of the "medical" sector.

MyMD Pharmaceuticals vs.

Navidea Biopharmaceuticals (NYSE:NAVB) and MyMD Pharmaceuticals (NASDAQ:MYMD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, community ranking, dividends, risk and analyst recommendations.

Navidea Biopharmaceuticals and MyMD Pharmaceuticals both received 0 outperform votes by MarketBeat users.

CompanyUnderperformOutperform
Navidea BiopharmaceuticalsOutperform Votes
No Votes
Underperform Votes
42
100.00%
MyMD PharmaceuticalsN/AN/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Navidea Biopharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
MyMD Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Navidea Biopharmaceuticals has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Comparatively, MyMD Pharmaceuticals has a beta of 2.17, indicating that its share price is 117% more volatile than the S&P 500.

MyMD Pharmaceuticals' return on equity of 0.00% beat Navidea Biopharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Navidea BiopharmaceuticalsN/A N/A -166.65%
MyMD Pharmaceuticals N/A -179.05%-108.14%

0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. Comparatively, 9.6% of MyMD Pharmaceuticals shares are owned by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are owned by company insiders. Comparatively, 2.6% of MyMD Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, MyMD Pharmaceuticals had 1 more articles in the media than Navidea Biopharmaceuticals. MarketBeat recorded 3 mentions for MyMD Pharmaceuticals and 2 mentions for Navidea Biopharmaceuticals. Navidea Biopharmaceuticals' average media sentiment score of 1.59 beat MyMD Pharmaceuticals' score of 0.00 indicating that MyMD Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Navidea Biopharmaceuticals Neutral
MyMD Pharmaceuticals Very Positive

MyMD Pharmaceuticals has lower revenue, but higher earnings than Navidea Biopharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.06N/A
MyMD PharmaceuticalsN/AN/A-$4MN/AN/A

Summary

MyMD Pharmaceuticals beats Navidea Biopharmaceuticals on 6 of the 9 factors compared between the two stocks.

Get MyMD Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for MYMD and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MYMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MYMD vs. The Competition

MetricMyMD PharmaceuticalsDiagnostic substances IndustryMedical SectorNASDAQ Exchange
Market Cap$4.60M$3.21B$5.13B$8.05B
Dividend YieldN/A0.69%2.83%3.97%
P/E RatioN/A153.19171.0518.36
Price / SalesN/A75.132,443.5179.27
Price / CashN/A16.8435.2731.30
Price / Book0.473.595.524.59
Net Income-$4M$32.98M$105.72M$213.84M
7 Day Performance-0.50%-1.27%0.64%0.31%
1 Month Performance-35.39%1.25%2.55%3.12%
1 Year Performance-96.38%-28.27%5.38%6.91%

MyMD Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NAVB
Navidea Biopharmaceuticals
0 of 5 stars
$0.03
flat
N/A-99.9%$3.00M$70,000.00-0.5011Gap Down
VRAX
Virax Biolabs Group
0 of 5 stars
$0.81
-2.4%
N/A-77.6%$1.25M$10,000.000.0011Positive News
BMRA
Biomerica
0 of 5 stars
$0.66
flat
N/A-59.1%$11.07M$5.34M-1.7862Short Interest ↑
TRIB
Trinity Biotech
0 of 5 stars
$1.55
-1.9%
N/A-64.8%$11.81M$56.83M-0.49398Short Interest ↑
CDIO
Cardio Diagnostics
1.6822 of 5 stars
$0.70
+1.4%
$1.35
+92.9%
-53.0%$15.88M$20,000.000.007Short Interest ↑
Positive News
ARTL
Artelo Biosciences
2.1251 of 5 stars
$1.51
-1.9%
$5.00
+231.1%
-17.2%$4.88MN/A-0.486Short Interest ↑
News Coverage
THMO
ThermoGenesis
2.8542 of 5 stars
$0.60
-1.6%
$5.00
+733.3%
-57.6%$4.77M$9.44M0.0025Short Interest ↓
Positive News
CLVR
Clever Leaves
0 of 5 stars
$2.79
+11.6%
N/A-57.7%$4.89M$17.42M-0.25296Short Interest ↑
NUWE
Nuwellis
0 of 5 stars
$0.26
flat
N/A-90.8%$4.69M$8.90M-0.0359Short Interest ↓
GNPX
Genprex
4.5918 of 5 stars
$2.36
-3.3%
$10.00
+323.7%
-93.3%$4.96MN/A0.0026Short Interest ↓
Gap Up

Related Companies and Tools

This page (NASDAQ:MYMD) was last updated on 5/30/2024 by MarketBeat.com Staff

From Our Partners